CORRECTION



Correction: Radiopharmacokinetic modelling and radiation dose assessment of ²²³Ra used for treatment of metastatic castration-resistant prostate cancer

Vera Höllriegl¹, Nina Petoussi-Henss¹, Kerstin Hürkamp¹, Juan Camilo Ocampo Ramos² and Wei Bo Li^{1*}

The online version of the original article can be found at https://doi.org/10.1186/s4065 8-021-00388-1.

*Correspondence:

Wei Bo Li

wli@helmholtz-muenchen.de ¹Institute of Radiation Medicine, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany

²Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1250 First Avenue, New York, NY 10065, USA Correction: EJNMMI Phys 8, 44 (2021) https://doi.org/10.1186/s40658-021-00388-1

Following publication of the original article [1], the authors reported an error in Table 5.

In Table 5 of our paper [1], we incorrectly cited part of the work of Lassmann and Nosske [2] by giving the value of 3.6 mGy/MBq for the liver absorbed dose coefficient due to alphas after intravenous administration of ²²³Ra-chloride. The correct value should be 36 mGy/MBq. Consequently, the following text in page 13 of our paper [1] has to be amended:

"The results of the present study were compared to the results of the compartmental modelling of Lassmann and Nosske [20] and were found to be lower (skeletal doses by a factor of 2.3–3.4, colon dose by a factor of 7.2), except for the doses to liver and kidneys, which were found to be higher by a factor of ca. 7."

Amended text:

"The results of the present study were compared to the results of the compartmental modelling of Lassmann and Nosske [20] and were found to be lower (skeletal doses by a factor of 2.3–3.4, colon dose by a factor of 7.2), except for the dose to kidneys, which was found to be higher by a factor of ca. 7. The dose coefficient to the liver shows a good agreement with the dose estimated by Lassmann and Nosske [2]".

The authors thank Lassmann and Eberlein for pointing out this error [3] and apologize for the incorrect citation.



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, and indicate of the stutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

The original article [1] has been updated.

Published online: 23 January 2025

References

- Höllriegl V, Petoussi-Henss N, Hürkamp K, et al. Radiopharmacokinetic modelling and radiation dose assessment of ²²³Ra used for treatment of metastatic castration-resistant prostate cancer. EJNMMI Phys. 2021;8:44. https://doi.org/10.1186/s40 658-021-00388-1.
- Lassmann M, Nosske D. Dosimetry of ²²³Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40(2):207–12. https://doi.org/10.1007/s00259-012-2265-y.
- Lassmann M, Eberlein U. Comparing absorbed doses and radiation risk of the α-emitting bone-seekers [²²³Ra]RaCl₂ and [²²⁴Ra]RaCl₂. Front Med. 2023;9:1057373. https://doi.org/10.3389/fmed.2022.1057373.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.